4 Largecap Revenue CAGR 10-15 Per Cent Stocks to Watch for Future Multibagger Potential: Sun Pharma, UltraTech Cement, Torrent Pharma and BHEL
- October 28, 2026
- Posted by: Manan Bisht
- Category: Best Stocks
Sun Pharma Rs 1,751.20. UltraTech Cement Rs 11,150. Torrent Pharma Rs 4,625. BHEL Rs 399.90. Market caps from Rs 1.52 lakh crore to Rs 4.21 lakh crore. Data as of 27 Oct 2026.
Quick Answer
Sun Pharma, UltraTech Cement, Torrent Pharma and BHEL are the 4 picks in this revenue CAGR 10-15 per cent stocks watchlist, with market caps between Rs 1.52 lakh crore and Rs 4.21 lakh crore. Sun Pharma stands out for the lowest PE of the group at 34.73, while UltraTech Cement offers 16.15% revenue growth in FY26. PE ratios run from 34.73 to 81.43, so compare each one with its industry PE before investing. All figures are as of 27 October 2026.
Revenue CAGR 10-15 per cent stocks to watch for multibagger potential start with a simple filter: size, a clean financial record and earnings that keep growing. Sun Pharma, UltraTech Cement, Torrent Pharma and BHEL meet that test, with market caps from Rs 1.52 lakh crore to Rs 4.21 lakh crore and Sun Pharma offering the lowest PE of the group at 34.73. Each of these companies has a four-year revenue CAGR between 10 and 15 per cent from FY22 to FY26, a return on equity of at least 10 per cent and profit growth in FY26 and in the latest quarter, and net profit rose in FY26 and in the latest quarter.
This list covers companies with a four-year revenue CAGR between 10 and 15 per cent from FY22 to FY26, a return on equity of at least 10 per cent and profit growth in FY26 and in the latest quarter, rising profit in FY26 and the latest quarter, market capitalisation above Rs 1,00,000 crore, and complete, verifiable financials, ranked by market capitalisation. Each company has a market cap above Rs 1 lakh crore. Investors screening revenue CAGR 10-15 per cent stocks usually begin with size and balance sheet strength, and this list follows the same logic. All figures are as of 27 October 2026 and are drawn from NSE and BSE data and company filings.
Click Here – Get Free Investment Predictions
What Are Revenue CAGR 10-15 Per Cent Stocks and Why Do They Attract Multibagger Interest?
Revenue CAGR 10-15 per cent stocks are shares of large companies whose sales compounded at 10 to 15 per cent a year between FY22 and FY26, a steady expansion that comes from real demand rather than one lucky year. The four here cover pharmaceuticals, cement and heavy electrical equipment.
Sales that grow at a double digit pace year after year show that customers keep coming back, which is the base on which profit growth is built. For revenue CAGR 10-15 per cent stocks, both FY26 and the latest quarter showed growth. Whichever way you read revenue CAGR 10-15 per cent stocks, the common thread is rising profit backed by complete financial data. With revenue CAGR 10-15 per cent stocks, comparing valuation, growth and balance sheet strength together works better than relying on one number. Every company in the table below passed a rising-profit check, and the figures for revenue CAGR 10-15 per cent stocks are complete. Read each company’s latest results and exchange filings before acting on revenue CAGR 10-15 per cent stocks.
Revenue CAGR 10-15 Per Cent Stocks at a Glance: Price, Market Cap, PE and ROE
Prices are closing prices as of 27 October 2026. Sun Pharma has the lowest PE of the group at 34.73, while Torrent Pharma posts the highest return on equity at 25.49%.
| Stock | CMP (Rs) | Market Cap (Rs Cr) | PE | Industry PE | ROE | Debt to Equity | 52-Week Range (Rs) |
|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | 1,751.20 | 4,20,793 | 34.73 | 36.42 | 13.74% | 0.06 | 1,583.70 to 2,046.90 |
| UltraTech Cement | 11,150 | 3,22,225 | 37.60 | 29.41 | 10.66% | 0.31 | 10,325.00 to 13,110.00 |
| Torrent Pharmaceuticals | 4,625 | 1,75,564 | 81.43 | 36.42 | 25.49% | 1.79 | 3,480.60 to 5,250.00 |
| Bharat Heavy Electricals | 399.90 | 1,51,744 | 52.69 | 45.89 | 10.76% | 0.23 | 229.54 to 464.00 |
Sun Pharma: 35.75% Profit CAGR Since FY22
Sun Pharmaceutical Industries is one of India’s largest drugmakers and sells generic and specialty medicines in India and overseas. It reported FY26 revenue of Rs 61,673.94 crore, up 12.69% year on year, and net profit of Rs 11,564.52 crore, up 5.32%. Net profit has compounded at 35.75% a year since FY22, while revenue has grown 11.62% a year. Operating margin was 31.47% in FY26. The debt-to-equity ratio is 0.06, which keeps interest costs low.
In the June 2026 quarter, revenue rose 11.93% to Rs 16,023.50 crore and net profit grew 26.41% to Rs 2,910.80 crore. The share price has gained 110.81% over five years. Domestic institutions raised their holding from 20.23% in September 2025 to 22.27% in September 2026. The stock trades at a PE of 34.73 against an industry PE of 36.42, below the sector average, with a return on equity of 13.74%.
UltraTech Cement: Profit Compounding at 3.36% a Year
UltraTech Cement is the largest cement producer in India by capacity, with plants and grinding units across the country. It reported FY26 revenue of Rs 89,089.04 crore, up 16.15% year on year, and net profit of Rs 8,188.35 crore, up 35.58%. Revenue has compounded at 13.81% a year since FY22. Operating margin was 19.71% in FY26. The debt-to-equity ratio is 0.31.
The stock trades at a PE of 37.60 against an industry PE of 29.41. The dividend yield is 2.19%. In the June 2026 quarter, revenue rose 15.49% to Rs 24,778.47 crore and net profit grew 17.24% to Rs 2,603.72 crore. Domestic institutions raised their holding from 16.65% in September 2025 to 20.86% in September 2026.
Torrent Pharma: 28.79% Profit CAGR Since FY22
Torrent Pharmaceuticals makes branded medicines for chronic therapies such as cardiac, gastro-intestinal and central nervous system care in India and overseas. It reported FY26 revenue of Rs 13,886.15 crore, up 20.34% year on year, and net profit of Rs 2,138.18 crore, up 11.87%. Net profit has compounded at 28.79% a year since FY22, while revenue has grown 12.38% a year. Operating margin was 22.70% in FY26.
In the June 2026 quarter, revenue rose 56.29% to Rs 4,909 crore and net profit grew 3.28% to Rs 566 crore. The share price has gained 194.63% over five years and 29.72% over the past year. Domestic institutions raised their holding from 9.28% in September 2025 to 12.87% in July 2026. The stock trades at a PE of 81.43 against an industry PE of 36.42, with a return on equity of 25.49%.
BHEL: 37.73% Profit CAGR Since FY22
Bharat Heavy Electricals is a government-owned maker of power generation, transmission, industrial and transportation equipment. It reported FY26 revenue of Rs 34,589.83 crore, up 20.08% year on year, and net profit of Rs 1,600.26 crore, up 199.73%. Net profit has compounded at 37.73% a year since FY22, while revenue has grown 12.54% a year. Operating margin was 10.18% in FY26. The debt-to-equity ratio is 0.23.
The stock trades at a PE of 52.69 against an industry PE of 45.89. In the September 2026 quarter, revenue rose 24.28% to Rs 9,553.01 crore and net profit grew 118.98% to Rs 820.94 crore. The share price has gained 488.34% over five years and 86.13% over the past year. Domestic institutions raised their holding from 18.62% in September 2025 to 21.88% in September 2026.
Revenue CAGR 10-15 Per Cent Stocks: Financial Comparison on Growth and Margins
The table compares scale and growth across these revenue CAGR 10-15 per cent stocks. Latest quarter means the most recent reported quarter for each company, and only metrics that are positive for every company are shown.
| Stock | Revenue (Rs Cr) | Net Profit (Rs Cr) | Revenue Growth (YoY) | 4-Year Revenue CAGR | 4-Year Net Profit CAGR | Operating Margin (Latest Quarter) |
|---|---|---|---|---|---|---|
| Sun Pharma | 61,673.94 | 11,564.52 | 12.69% | 11.62% | 35.75% | 32.52% |
| UltraTech Cement | 89,089.04 | 8,188.35 | 16.15% | 13.81% | 3.36% | 20.83% |
| Torrent Pharma | 13,886.15 | 2,138.18 | 20.34% | 12.38% | 28.79% | 33.73% |
| BHEL | 34,589.83 | 1,600.26 | 20.08% | 12.54% | 37.73% | 13.94% |
Check the Univest Screener for live data on these revenue CAGR 10-15 per cent stocks
Institutional Holding in Sun Pharma, UltraTech Cement, Torrent Pharma and BHEL
Institutional holding shows who is backing these revenue CAGR 10-15 per cent stocks alongside the promoter. The table uses the latest reported quarter for each. Sun Pharma has the deepest institutional backing, with FII and DII together holding 36.63% as of September 2026. Domestic institutions increased their holding over the past year in Sun Pharma (from 20.23% to 22.27%), UltraTech Cement (from 16.65% to 20.86%), Torrent Pharma (from 9.28% to 12.87%) and BHEL (from 18.62% to 21.88%).
| Stock | Promoter | FII | DII | Public | Quarter |
|---|---|---|---|---|---|
| Sun Pharma | 52.68% | 14.36% | 22.27% | 10.70% | September 2026 |
| UltraTech Cement | 58.48% | 12.69% | 20.86% | 7.97% | September 2026 |
| Torrent Pharma | 60.78% | 17.97% | 12.87% | 8.38% | July 2026 |
| BHEL | 58.17% | 9.94% | 21.88% | 10.02% | September 2026 |
Risks to Weigh in Revenue CAGR 10-15 Per Cent Stocks
Being careful with revenue CAGR 10-15 per cent stocks means looking at what can slow the story as well as what can speed it up. Four points matter most:
- Past growth may not repeat.
- Share prices can move sharply in either direction.
- Valuation: Torrent Pharma trades at a PE of 81.43 against an industry PE of 36.42, so earnings need to keep growing to support the price.
- Concentration: Holding all 4 names puts the allocation in one sector, so size each position to match your risk appetite.
How to Choose Between Revenue CAGR 10-15 Per Cent Stocks
Picking from revenue CAGR 10-15 per cent stocks comes down to four checks, applied in order.
- Check balance sheet strength first, and prefer a debt-to-equity ratio below 1 for non-financial companies.
- Compare each PE with the industry PE (29.41 to 45.89) and ask whether the growth rate justifies any gap.
- Track net profit growth, the operating margin and the return on equity in every quarterly result.
- Stagger entries across quarters and review institutional holding every reporting season.
Download the Univest iOS App or Univest Android App to track Sun Pharma, UltraTech Cement, Torrent Pharma and BHEL live prices.
Conclusion
Among revenue CAGR 10-15 per cent stocks, Sun Pharma stands out for the lowest PE of the group at 34.73, UltraTech Cement for 16.15% revenue growth in FY26, Torrent Pharma for the highest return on equity at 25.49% and BHEL for the fastest profit growth, 37.73% a year since FY22. Which one suits a portfolio depends on how much valuation risk it can carry, so staggering entries and reviewing each quarterly result is a sound habit. Investors comparing revenue CAGR 10-15 per cent stocks should rank them on growth, financial strength and the price paid, and anyone who wants personalised guidance can consult a SEBI-registered advisor before acting.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions on Revenue CAGR 10-15 Per Cent Stocks to Watch
Which are the best revenue CAGR 10-15 per cent stocks to watch for multibagger potential?
Ans. Sun Pharma, UltraTech Cement, Torrent Pharma and BHEL are the 4 names this list highlights, with market caps of Rs 4,20,793 crore, Rs 3,22,225 crore, Rs 1,75,564 crore and Rs 1,51,744 crore respectively. Sun Pharma is notable for the lowest PE of the group at 34.73. UltraTech Cement stands out for 16.15% revenue growth in FY26. Torrent Pharma offers the highest return on equity at 25.49%. BHEL brings the fastest profit growth, 37.73% a year since FY22. These are watchlist names for revenue CAGR 10-15 per cent stocks, not recommendations, so match each one to your own risk profile and time horizon.
Is Torrent Pharma a good stock for long-term investors?
Ans. Torrent Pharma has a return on equity of 25.49%, a PE of 81.43 against an industry PE of 36.42 and a market cap of Rs 1,75,564 crore. Net profit has compounded at 28.79% a year since FY22, and FY26 revenue rose 20.34% while June 2026 quarter net profit grew 3.28%. Long-term returns in revenue CAGR 10-15 per cent stocks depend on earnings growth and the price paid at entry, so staggering purchases and consulting a SEBI-registered advisor is sensible.
Can BHEL become a multibagger from here?
Ans. BHEL has already gained 488.34% in five years, so another multi-fold move would need sustained earnings growth. A multibagger outcome in revenue CAGR 10-15 per cent stocks requires earnings to keep growing faster than the market for several years. Net profit has compounded at 37.73% a year since FY22, and FY26 revenue rose 20.08%. At a PE of 52.69 against an industry PE of 45.89, valuation should be checked against that growth before investing.
What is the market cap of Sun Pharma, UltraTech Cement, Torrent Pharma and BHEL?
Ans. As of 27 October 2026, Sun Pharma has a market cap of Rs 4,20,793 crore, UltraTech Cement has a market cap of Rs 3,22,225 crore, Torrent Pharma has a market cap of Rs 1,75,564 crore and BHEL has a market cap of Rs 1,51,744 crore. All of them qualify as largecaps. Market cap changes daily with the share price, so check the latest figure on the Univest Screener or on NSE before taking a decision on revenue CAGR 10-15 per cent stocks.
What are the risks of investing in revenue CAGR 10-15 per cent stocks?
Ans. The main risks are market swings, slower growth than expected and valuations that already reflect good news. Companies with strong balance sheets and steady earnings handle these better. Torrent Pharma trades at a PE of 81.43 against an industry PE of 36.42, so earnings growth needs to hold up.
Why is Torrent Pharma trading at a PE of 81.43?
Ans. Torrent Pharma’s PE of 81.43 compares with an industry PE of 36.42. The market is paying a premium for a return on equity of 25.49%, profit growth of 28.79% a year since FY22 and FY26 revenue growth of 20.34%, which also means the stock is more sensitive if growth slows. Investors in revenue CAGR 10-15 per cent stocks who are comfortable with higher valuation risk may prefer to stagger purchases instead of investing in one go.
How much do institutions hold in Sun Pharma, UltraTech Cement, Torrent Pharma and BHEL?
Ans. As of the latest reported quarter, FII and DII together hold 36.63% of Sun Pharma (14.36% and 22.27%), 33.55% of UltraTech Cement (12.69% and 20.86%), 30.84% of Torrent Pharma (17.97% and 12.87%) and 31.82% of BHEL (9.94% and 21.88%). Rising institutional holding is a useful signal in revenue CAGR 10-15 per cent stocks, though it should be read with earnings trends rather than on its own.
